Law360, New York (November 9, 2016, 10:42 PM EST) -- The U.S. Food and Drug Administration on Wednesday heard sharply divergent views about off-label promotion of drugs and medical devices, with manufacturers and BigLaw attorneys urging more leeway while consumer advocates sounded alarm bells about risks to public health.
The meeting, which was announced in August, lasted eight hours on Wednesday and will continue on Thursday. It comes as the FDA is revisiting its restrictions on off-label promotion after losing multiple First Amendment challenges in recent years.
Here are five takeaways from the forum's first day.
Constitutional Concerns Highlighted
Several pro-industry speakers suggested that the FDA is in denial about the impact of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!